Jessica Perini, MD
Endocrinology, Diabetes & Metabolism · Morgantown, WVNPI 1689751331
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Amgen accounts for 61.9% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $4,144 and has fallen 70.2% since, to $1,234 in 2025.
Across 150 payments — averaging $65.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- Medtronic$726
- Novo Nordisk$485
- Insulet Corporation$272
- Lilly USA, LLC$219
- Corcept Therapeutics$213
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$5,00051%
- Food & beverage$4,77049%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 18 | $6,054 |
| Medtronic(2 entities) | 23 | $726 |
| Novo Nordisk | 28 | $485 |
| Insulet Corporation | 6 | $272 |
| Lilly USA, LLC | 12 | $219 |
| Corcept Therapeutics | 3 | $213 |
| Sanofi-aventis U.S. LLC | 6 | $202 |
| Dexcom, Inc. | 7 | $190 |
| Abbott | 7 | $162 |
| Cequr Corporation | 2 | $160 |
| Sequel Med Tech, LLC | 3 | $156 |
| Xeris Pharmaceuticals, Inc. | 7 | $152 |
| Bayer | 2 | $145 |
| Johnson & Johnson | 2 | $128 |
| Tandem Diabetes Care, Inc. | 3 | $105 |
| Ascendis Pharma Endocrinology Inc | 2 | $49 |
| Novartis | 2 | $49 |
| Antares Pharma, Inc. | 2 | $47 |
| Kyowa Kirin, Inc. | 2 | $38 |
| Pfizer | 2 | $37 |
| Shire North American Group Inc | 2 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $23 |
| Nevro Corp. | 1 | $21 |
| BETA Bionics, Inc. | 2 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Halozyme Inc | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$5,222
- MINIMED 780G$356
- EVENITY$245
- Omnipod$150
- TZIELD$125
- Kerendia$125
- INVOKANA$123
- Korlym$122
- CeQur Simplicity$105
How this compares
$9,775 in reported general payments places this provider in the 80th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $130,752 |
| MounjaroTirzepatide | 49 | $78,535 |
| TrulicityDulaglutide | 46 | $75,356 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $39,379 |
| JardianceEmpagliflozin | 27 | $38,247 |
| TymlosAbaloparatide | 12 | $26,981 |
| Teriparatide | 11 | $25,561 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $11,993 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $8,660 |
| SynthroidLevothyroxine Sodium | 54 | $4,817 |
| Novolog FlexpenInsulin Aspart | 20 | $4,225 |
| Gvoke Hypopen 1-PackGlucagon | 13 | $4,021 |
| NovologInsulin Aspart | 14 | $3,263 |
| Levothyroxine Sodium | 224 | $2,895 |
| Hydrocortisone | 22 | $1,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $219 | $153,89195 claims |
| Novo NordiskOzempic, Novolog | $485 | $134,01590 claims |
| Boehringer IngelheimJardiance | $17 | $38,24727 claims |
| Radius Health, Inc.Tymlos | $14 | $26,98112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Morgantown
- Jennifer TurnerMorgantown$6K
- Adnan HaiderMorgantown$3K
- Jennifer GiordanoMorgantown$2K
- Nadia BarghouthiMorgantown$1K
- Apoorva IyerMorgantown$1K
- Jeffrey Zen-Ji RicoMorgantown$1K
- Tariq LatifMorgantown$844
- Mehjabeen SadiqMorgantown$684
- Sarah FatimaMorgantown$292
- Ann-Marie BusickMorgantown$227
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.